AccueilAccueil>Séminaires

Séminaires & conférences

AU VUE DE LA SITUATION SANITAIRE, TOUS NOS SEMINAIRES SONT ACTUELLEMENT EN VISIOCONFERENCE. SI VOUS SOUHAITEZ ASSISTER A L'UN DEUX, MERCI DE CONTACTER BRIGITTE JARRIN QUI VOUS ENVERRA LE LIEN. secretariat@crc.jussieu.fr

   

 


     
Thursday, March 11, 13h30

 SÉMINAIRE TECHNIQUE

                                         

 La cytométrie de masse dans tous ses états :

de la recherche clinique à l'imagerie

Catherine BLANC et Aurélien CORNEAU,

(CyPS, Pitié-Salpêtrière, Paris)


 Invités par Chiara MAIURI

 ___________________________________________ 

     
Thursday, March 18, 13h30

 SÉMINAIRE EATI

                                         

 Dynamics of immune cell coopérations underlying

tumor régressions : lessons from mouse models

Nadège BERCOVICI (Institut Cochin, Paris)

 


 Invitée par Jonathan POL

 ___________________________________________   

 
Thursday, March 25, 13h30

SÉMINAIRE EXTERIEUR

                                         

 Quantifyng the evolutionary dynamics

of human cancers

Trevor GRAHAM (Barts Institute, QMUL London)

Invité par Jessica Zucman-Rossi et Angélique Gougelet

/////

 

The fundamental evolutionary parameters that define cancer evolution, such as the mutation rate per cell division and selective advantage conferred by each mutation, remain poorly characterised. Here I will discuss how these parameters can be derived from routinely-available cancer genome sequencing data, via statistical inference of mathematical population genetics models of clonal evolution. We measure that positively selected mutations can cause fitness increases as large as 50%, and also explore the dynamics of negatively-selected mutations (neoantigens) in a growing tumour. These quantitative measurements of cancer evolution enable mechanistic forecasting of the future evolution of a tumour.

/////

 ___________________________________________ 

     Thursday, April 1, 13h30

 SÉMINAIRE TECHNIQUE

                                         

 Présentation de la cytométrie spectrale

EN ATTENTE (-------------)

 


 Invité par Hélène Fohrer-Ting

 ___________________________________________   
Thursday, April 8, 13h30

 SÉMINAIRE EXTERIEUR

                                         

 Titre en attente

Benjamin BONNARD (Equipe Fabienne Foufelle)

 


 Invité par Angélique Gougelet et Guilhem Lignon

 ___________________________________________   
      

  
Thursday, April 22, 13h30

SÉMINAIRE EXTERIEUR

                                         

 Novel precision mouse models of liver cancer

Amaia LUJAMBIO (Icahn school of médicine

at mount sinai)

Invitée par Jessica Zucman-Rossi, Chantal Desdouets, Angélique Gougelet

/////

 

Hepatocellular carcinoma (HCC) represents a major health problem, causing more than 700,000 deaths annually. Although HCC treatment has greatly improved over the last decades, HCC patients diagnosed at advanced stages are ineligible for curative ablative therapies such as liver resection or transplantation. Several multikinase inhibitors, such as sorafenib, regorafenib, and lenvatinib, are approved for the treatment of advanced HCC patients but provide limited survival benefits. Recently, nivolumab and pembrolizumab, two PD1 (programmed cell death 1) immune checkpoint inhibitors, were approved for second line HCC treatment after showing unprecedented results in phase II clinical trials. However, not all patients are sensitive. It is therefore clear that there is an urgent need to identify novel therapies that are more effective and biomarkers for optimal patient selection.To this end, we have created a series of novel mouse models of HCC, each model recapitulating genetic alterations that are frequent in HCC patients. The model is based on the hydrodynamic tail vein delivery of genetic elements to overexpress oncogenes (with transposon-based vectors) and delete tumor suppressor genes (with CRISPR-based vectors). We have established cell lines from each model (13 in total) and are now performing drug and CRISPR screens to identify novel drug targets that are specific for each model. In addition, we have modified the hydrodynamic strategy to interrogate how genetic alterations relevant to human disease affect immune surveillance and response to immunotherapies. In this case, we modulate the immunogenicity of the liver tumors by also expressing model antigens. With this model, we have shown that beta-catenin activation is a novel mechanism of immune escape and immune resistance in HCC. We are currently using this platform to identify additional mechanisms of immune escape in HCC and define novel biomarkers for patient selection..

/////

      

  
Thursday, May 20, 13h30

SÉMINAIRE EXTERIEUR

                                         

 Titre en attente

Federico MINGOZZI (Sparks Therapeutics)

Invité par Jessica Zucman-Rossi et Sébastien Lacroix-Desmazes

 ___________________________________________  


       

 

Les Outils